INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted approach that potentially allows for safer deep B cell depletion.INB-619 is the first pan-gamma delta (γδ) T cell engager designed to significantly expand multiple γδ T cell subsets for efficient, durable target elimination.INB-619 achieved robust γδ T cell expansion and complete B cell depletion across both h ...